Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An exploratory Phase IIa study of JJP-1212 in autoimmunity

Next Previous
Trial Profile

An exploratory Phase IIa study of JJP-1212 in autoimmunity

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs JJP 1212 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 19 Mar 2024 New trial record
  • 15 Jun 2023 According to a JJP Biologics media release, the successful manufacturing of the first ever clinical GMP batch of DS and DP for JJP-1212, JJP Biologics secures sufficient supply for their plans to go into healthy subjects in their first ever Phase I clinical trial, and when successful, subsequent Phase II in the rare autoimmune blistering disease linear IgA bullous dermatosis (LABD) and an exploratory Phase IIa in autoimmunity.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top